Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relmada Therapeutics, Inc. - Common Stock (NQ:RLMD)

0.2759 -0.0241 (-8.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relmada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Relmada Therapeutics: Q1 Earnings Insights
Via Benzinga
Earnings Preview For Relmada Therapeutics
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Bowlero, and Integra and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Preview: Relmada Therapeutics's Earnings
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Investor Alert: Investigation Concerning Potential Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 05/11/2023 -- An investigation was announced for investors of Relmada Therapeutics, Inc. (NASDAQ:RLMD) shares over potential securities laws violations by Relmada... 
Via SBWire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Relmada Therapeutics, Inc. (RLMD) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
RELMADA ALERT: Bragar Eagel & Squire, P.C. is Investigating Relmada Therapeutics, Inc. on Behalf of Relmada Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
RLMD INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ: VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major... 
Via Benzinga
Looking Into Relmada Therapeutics's Recent Short Interest
Relmada Therapeutics's (NASDAQ:RLMD) short percent of float has fallen 13.6% since its last report. The company recently reported that it has 1.72 million shares sold short, which is 5.78% of all... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by over 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Looking Into Relmada Therapeutics's Recent Short Interest
Relmada Therapeutics's (NASDAQ:RLMD) short percent of float has fallen 8.99% since its last report. The company recently reported that it has 2.77 million shares sold short, which is 9.31% of all... 
Via Benzinga
S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results
U.S. stocks traded higher toward the end of trading, with the NASDAQ gaining around 100 points on Thursday. 
Via Benzinga
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 138 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.